Physician profile
Chelsey E Windham
NPI 1477824902
$3,940.51
in general payments reported to CMS, 2019-2025
22 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $195 · 2023: $276 · 2024: $1,257 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.76 | 2021-2025 | |
| Novo Nordisk INC | $645.40 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $414.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $373.51 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $246.88 | 2021-2025 | Trintellix, Glassia |
| Amgen INC. | $232.64 | 2023-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $232.12 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.77 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $141.05 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $133.48 | 2024-2025 | Auvelity |
| Cvrx, INC. | $124.14 | 2025 | Barostim Neo System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.68 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $60.51 | 2024-2025 | Spravato |
| Exact Sciences Corporation | $54.55 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Actelion Pharmaceuticals US, INC. | $46.72 | 2025 | Uptravi, Opsumit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $46.49 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $34.12 | 2023-2024 | Veozah |
| Abbott Laboratories | $24.84 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $18.71 | 2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $15.78 | 2025 | Voquezna |
| Currax Pharmaceuticals LLC | $13.27 | 2024 | Contrave |
| Idorsia Pharmaceuticals US INC | $13.24 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsey Windham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.